Share Prices & Company Research

Stockbroking

Novacyt S.A

Current Price 6.03p Bid 7.00p Ask 9.00p Change 0.00%
Last Updated: 14/11/2019 14:00. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Novacyt S.A. is a rapidly growing, international diagnostics group with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform, NOVAPrep, and molecular platform, genesig, Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products across an extensive international distributor network. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

Financial Highlights Year Ended 31/12/2018

Turnover
£13.72m
Operating Profit
£-1.39m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
-0.62

Key Personnel

Graham David Mullis
Chief Executive Officer
Anthony William Dyer
Chief Financial Officer
James Christopher Wakefield
Non-Executive Chairman
Juliet Thompson
Non-Executive Director
Dr Edwin Snape
Non-Executive Director
Dr Andrew John William Heath
Non-Executive Director
Jean-Pierre Jacques Crinelli
Non-Executive Director

Stock Details

EPIC
NCYT
ISIN
FR0010397232
Shares in Issue
58,094,754
Market cap
£4.65m

Analyst Views (0)

Strong Buy
 
0.00%
Buy
 
0.00%
Hold
 
0.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
8.00p
Bid Price
7.00p
Ask Price
9.00p
Volume
0
Change Today
0.00p
% Change Today
0.00%
Open
0.00p
Previous Close
8.00p
Intraday High
0.00p
Intraday Low
0.00p
52 Week High
36.50p
52 Week Low
6.50p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Novacyt S.A Intra-day Chart

Novacyt S.A News

News in this section is provided by AJ Bell

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Tangible Assets
1.2
1.6
Intangible Assets & Goodwill
21.1
21.3
Investments & Other Non-Current Assets
0.2
0.2
Total Non-Current Assets
22.5
23.1
Inventory
2.4
1.9
Trade & Receivables
3.9
3.8
Cash & Receivables
1.1
4.4
Other Current Assets & Assets Held for Resale
2.6
0.8
Total Assets
32.5
34.0

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Short Term Liabilities
9.8
7.8
Long Term Liabilities
2.5
1.3
Other Liabilities / Pension etc
0.1
0.0
Total Liabilities
12.4
9.1

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Net Assets
20.1
24.9

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Share Capital
2.5
2.5
Minority Interests
0.0
0.0
Retained Earnings
-38.1
-33.3
Share Premium Account
58.3
58.3
Other Equity
-2.6
-2.6
Total Equity
20.1
24.9

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Cashflow from Operating Activities
-1.3
-4.7
Cashflow Before Financing
-4.0
-7.5
Increase / Decrease in Cash
-3.2
1.5

Income (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Turnover
13.7
15.0
Cost of Sales
5.1
6.0
Gross Profit
8.6
8.9
Operating Profit
-1.4
-4.1
Pre-Tax Profit
-2.1
-5.4
Profit / Loss for the Year
-4.7
-5.4
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.